A Study of Vemurafenib in Participants With Metastatic Melanoma
An Open-Label, Multicenter Study to Assess the Safety of RO5185426 (Vemurafenib) in Patients With Metastatic Melanoma
Sponsor: Hoffmann-La Roche
This PHASE3 trial investigates Malignant Melanoma and is currently completed. Hoffmann-La Roche leads this study, which shows 10 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
10 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Jan 2018 [monthly]
Completed PHASE3
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain, Aachen, Germany, Aarhus C, Denmark, Adana, Turkey (Türkiye), Adelaide, Australia, Amsterdam, Netherlands, Ankara, Turkey (Türkiye), Antalya, Turkey (Türkiye), Arequipa, Peru, Athens, Greece and 227 more location s